Latest news
Iconovo adds business development experience with new CEO
So far, 2020 has brought several advancements for the Swedish dry powder inhaler company Iconovo. A major stepping stone was the change of CEO in April.…
Iconovo signs regional licensing agreement for ICOcap® formulations with BNC Korea
Iconovo announce that the company has signed a know-how license agreement granting BNC Korea Co Ltd the exclusive rights to use the know-how to manufacture…
Press releases
Oct 27, 2023, 14:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Oct 27, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Oct 17, 2023, 21:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
mfn-cus-disclaimer
Sep 26, 2023, 23:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Sep 26, 2023, 23:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 23:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 09:15
News
IR
Swedish
Corporate Action
Other
Sep 26, 2023, 09:15
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
English
Corporate Action
Other
Aug 30, 2023, 14:00
News
IR
Swedish
Corporate Action
Other
Aug 29, 2023, 09:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Aug 22, 2023, 09:00
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Aug 22, 2023, 09:00
News
IR
English
Corporate Action
Other
mfn-cus-disclaimer
Aug 17, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Aug 17, 2023, 08:15
News
IR
English
Regulatory
MAR
Corporate Action
Other
Aug 16, 2023, 08:15
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
